Susquehanna International Group, LLP Arbutus Biopharma Corp Put Options Transaction History

Susquehanna International Group, LLP

$560 Billion
Q3 2024

Put Options

23 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$3.12 - $4.56 $241,176 - $352,487	77,300 Added 125.28%	139,000 $535,000
Q2 2024 Aug 15, 2024	BUY	$2.52 - $3.63 $112,644 - $162,261	44,700 Added 262.94%	61,700 $190,000
Q1 2024 May 07, 2024	SELL	$2.26 - $2.92 $143,058 - $184,836	-63,300 Reduced 78.83%	17,000 $43,000
Q4 2023 Feb 14, 2024	SELL	$1.69 - $2.54 $27,547 - $41,402	-16,300 Reduced 16.87%	80,300 $200,000
Q3 2023 Nov 14, 2023	SELL	$1.9 - $2.27 $35,340 - $42,222	-18,600 Reduced 16.15%	96,600 $196,000
Q2 2023 Aug 11, 2023	SELL	$2.24 - $3.06 $16,352 - $22,338	-7,300 Reduced 5.96%	115,200 $264,000
Q1 2023 May 16, 2023	SELL	$2.23 - $3.1 $433,289 - $602,330	-194,300 Reduced 61.33%	122,500 $371,000
Q4 2022 Feb 14, 2023	BUY	$1.91 - $2.85 $88,815 - $132,525	46,500 Added 17.2%	316,800 $738,000
Q3 2022 Nov 14, 2022	SELL	$1.88 - $2.88 $448,004 - $686,304	-238,300 Reduced 46.85%	270,300 $516,000
Q2 2022 Aug 15, 2022	SELL	$1.98 - $3.17 $788,436 - $1.26 Million	-398,200 Reduced 43.91%	508,600 $1.38 Million
Q1 2022 May 16, 2022	SELL	$2.42 - $3.98 $97,042 - $159,598	-40,100 Reduced 4.23%	906,800 $2.7 Million
Q4 2021 Feb 14, 2022	BUY	$3.11 - $4.61 $417,984 - $619,584	134,400 Added 16.54%	946,900 $3.68 Million
Q3 2021 Nov 15, 2021	BUY	$2.65 - $4.62 $807,455 - $1.41 Million	304,700 Added 60.0%	812,500 $3.49 Million
Q2 2021 Aug 11, 2021	SELL	$2.5 - $3.51 $40,500 - $56,862	-16,200 Reduced 3.09%	507,800 $1.54 Million
Q1 2021 May 17, 2021	SELL	$3.14 - $4.84 $1.48 Million - $2.28 Million	-471,400 Reduced 47.36%	524,000 $1.75 Million
Q4 2020 Feb 16, 2021	BUY	$2.76 - $4.97 $1.9 Million - $3.42 Million	688,000 Added 223.81%	995,400 $3.53 Million
Q3 2020 Nov 16, 2020	BUY	$1.75 - $6.2 $506,100 - $1.79 Million	289,200 Added 1589.01%	307,400 $962,000
Q2 2019 Aug 14, 2019	BUY	$1.46 - $4.44 $4,234 - $12,876	2,900 Added 18.95%	18,200 $38,000
Q4 2018 Feb 14, 2019	BUY	$3.5 - $9.66 $10,500 - $28,980	3,000 Added 24.39%	15,300 $59,000
Q3 2018 Nov 14, 2018	SELL	$7.85 - $12.35 $54,165 - $85,215	-6,900 Reduced 35.94%	12,300 $116,000
Q2 2018 Aug 14, 2018	SELL	$5.0 - $7.35 $204,000 - $299,880	-40,800 Reduced 68.0%	19,200 $140,000
Q1 2018 May 15, 2018	BUY	$4.4 - $6.05 $219,120 - $301,290	49,800 Added 488.24%	60,000 $300,000
Q3 2017 Nov 14, 2017	BUY	$3.4 - $7.0 $34,680 - $71,400	10,200	10,200 $63,000

Others Institutions Holding ABUS

# of Institutions

155

Shares Held

99.5M

Call Options Held

2.31M

Put Options Held

525K

Morgan Stanley New York, NY

21.7M
Shares

$69 Million
0.01% of portfolio
Whitefort Capital Management, LP New York, NY

12.9M
Shares

$40.9 Million
26.34% of portfolio
Black Rock Inc. New York, NY

11.6M
Shares

$36.7 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

8.92M
Shares

$28.4 Million
0.0% of portfolio
Two Seas Capital LP Rye, NY

8.39M
Shares

$26.7 Million
10.86% of portfolio

View Full List

About Arbutus Biopharma Corp

Ticker ABUS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,951,008
Market Cap $477M
Description
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...

More about ABUS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Account